Critically, we observed that the pharmacological agent C29 (ERRα inverse agonist) ameliorated the HFD-induced NAFLD in the ERRα3SA mice concomitantly with the reversal of dyslipidemia and hyperglycemia, thereby increasing insulin responsiveness. This evidence concerns the gene ESRRA and metabolic dysfunction-associated steatotic liver disease.